A2AR blockade and programmed death-1 (PD-1)/cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) monoclonal antibody (mAb) combined therapy also illustrated impressive effects in a variety of syngeneic tumor models [112]. Here, CTLA4 is linked to neoplasm.